Ironwood Pharma (IRWD) Tops Q3 EPS by 29c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LVS
9. LRCX
10. MRK

Go back to Ironwood Pharma (IRWD) Tops Q3 EPS by 29c

Ironwood (IRWD) Updates on Q3 Activity; FDA Approves LINZESS, Linaclotide Gets Nod from CHMP

October 16, 2012 7:06 AM EDT

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today provided an update on its third quarter 2012 and recent business activities.

Third Quarter 2012 and Recent Highlights

LinaclotideThe U.S. Food and Drug Administration (FDA) approved LINZESS as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS can help to relieve abdominal pain and constipation associated with IBS-C, and constipation and hard stools associated with CIC. Ironwood and Forest Laboratories, Inc. expect LINZESS to be available to U.S. patients in... More